WO2001045742A1 - Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof - Google Patents
Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof Download PDFInfo
- Publication number
- WO2001045742A1 WO2001045742A1 PCT/KR2000/001508 KR0001508W WO0145742A1 WO 2001045742 A1 WO2001045742 A1 WO 2001045742A1 KR 0001508 W KR0001508 W KR 0001508W WO 0145742 A1 WO0145742 A1 WO 0145742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- polyethylene glycol
- water
- range
- block copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention relates to a liquid composition for drug delivery. More specifically, the present invention relates to a liquid polymeric composition comprising a water-soluble, biocompatible, liquid polyethylene glycol derivative; a biodegradable block copolymer which can be dissolved in the liquid polyethylene glycol derivative but which can not be dissolved in water; and a physiologically active substance, wherein when injected into a living body, the composition forms a polymeric implant containing the physiologically active substance that gradually releases the physiologically active substance and then decomposes into materials harmless to the human body.
- biodegradable polymers have been widely used in the medical field as surgical sutures, tissue regenerative induction membranes, protective membranes for the treatment of wounds, and drug delivery systems.
- biodegradable polymers polylactide (PLA), polyglycolide (PGA) and a copolymer (PLGA) of lactide and glycolide have been the subject of many studies and are commercially available since they have good biocompatibility and are decomposable in the body to harmless materials such as carbon dioxide, water, etc.
- biodegradable polymeric drug delivery system is a system wherein a drug is contained in a biodegradable polymer matrix which has the disadvantage of having to be implanted via surgery
- a biodegradable polymer matrix which has the disadvantage of having to be implanted via surgery
- polymeric microspheres and nanospheres are known in the art
- those systems have disadvantages in that they require special preparation methods
- biodegradable polymers used can only be dissolved in organic solvents preparation requires the use of organic solvents harmful to the human body and therefore any residual solvent remaining after preparation of the microspheres must be completely removed
- some drugs such as polypeptides and proteins may lose their physiological activity after contacting organic solvents
- U S Patent No 5,384,333 discloses an injectable drug delivery composition in which a pharmacologically active substance is contained in a copolymer comprising a hydrophilic part and a hydrophobic part
- the composition is in a solid state at temperatures ranging from 20 °C to 37 °C and is in a fluid state at temperatures ranging from 38 °C to 52 °C
- the composition has to be heated to a relatively high temperature such as 38 °C to 52 °C, immediately before use and it is difficult to uniformly distribute the drug in the polymeric composition
- U S Patent No 5,612,052 discloses a block copolymer composition characterized by a hydrophobic polyester (A) and a hydrophilic polyethylene oxide (B) which are combined in the form of an A-B-A triblock, which is then hydrated by contacting it with water which then forms a hydrogel
- A hydrophobic polyester
- B hydrophilic polyethylene oxide
- the drug incorporated in this composition is rapidly released and therefore a special means of using separate biodegradable fine particles containing the drug, in the form of a suspension, is required
- U S Patent No 5,702,717 discloses a system for delivery of proteins containing A-B- A type block copolymers comprising hydrophobic biodegradable polyesters (A) and hydrophilic polymeric polyethylene oxide (B), which undergo sol-gel phase transition in an aqueous solution at particular temperatures and concentrations.
- A hydrophobic biodegradable polyesters
- B hydrophilic polymeric polyethylene oxide
- This system takes advantage of a thermal property of the block copolymers in that they are dissolved in water at temperatures below 20 °C and undergo phase transition to form a gel at temperatures above about 30 °C.
- this system uses a composition in which the drug is dissolved together with the polymers in an aqueous solution at low temperatures, the resulting solution is then injected into a human body via a syringe.
- the polymers undergo phase transition to form a gel and then the drugs incorporated therein is slowly released. Since the polymers are biodegradable, the preparation of this composition does not require the use of organic solvents or any special methods and the composition can be simply sterilized by using a membrane filter.
- this method has several drawbacks in that since the constituents of the block copolymers are degradable polymers and can be hydrolyzed with water, they cannot be commercialized in the form of a polymeric aqueous solution. In addition, since the composition needs to be dissolved in water before use which requires more than half an hour, it is difficult for this composition to be converted into a commercial product.
- 5,599,552 discloses a composition wherein a water-insoluble biodegradable thermoplastic polymer is dissolved in a water-miscible organic solvent, and the resulting composition can be implanted where it then undergoes a phase transition when in contact with water or body fluids
- a mono-molecular organic solvent is used to dissolve the biodegradable thermoplastic polymer.
- mono-organic solvents such as N-methyl-2-pyrrolidone, ethyl lactate, dimethylsulfoxide, etc., cause side effects such as cell dehydration and tissue necrosis, etc. and they may also cause severe pain at the application sites.
- 5,607,686 discloses a liquid polymeric composition prepared by mixing a hydrophilic liquid polymer, instead of a mono-molecular organic solvent, with a water-insoluble hydrophobic polymer.
- a hydrophilic liquid polymer instead of a mono-molecular organic solvent
- a water-insoluble hydrophobic polymer When contacted with water the composition undergoes a phase transition and forms an implant and thus it does not cause a the rapid volume reduction and it has no special side effects due to the good cyto-compatibility of the low molecular weight polyethylene oxide.
- the water-insoluble hydrophobic polymers used are not biodegradable.
- the preparation of the composition requires heating to about 80 °C in order to achieve uniform mixing of the water-insoluble hydrophobic polymer and the hydrophilic liquid polymer.
- this system may be suitable to use for adherence prevention and wound protection without any physiologically active substance, but it is not suitable for delivery of physiologically active substances, particularly peptide or protein medicines because peptide and protein medicines lose their activities at high temperatures. Furthermore, protein medicines are water soluble, thus it is very difficult to uniformly incorporate them into the composition. In addition, it is not disclosed in this patent how the drugs or physiologically active substances can be uniformly incorporated in the polymeric composition.
- polylactide, polyglycolide and their copolymers can be mixed with polyethylene glycol at high temperatures of 80 °C in order to obtain a uniform composition
- the composition undergoes phase separation when it stands for a long period of time due to the lowered affinity of the polylactide, the polyglycolide or their copolymers with polyethylene glycol. Therefore, it is very difficult to maintain a uniform composition.
- Sterilization steps are necessary in the preparation of implant formulations.
- Existing sterilization methods are unsuitable for implant formulations due to properties of the implant compositions or because the methods are uneconomical or too complicated.
- the composition cannot be sterilized by simple methods such as membrane filtration, and must be sterilized by radiation exposure or EO (ethylene oxide) gas methods.
- EO ethylene oxide
- radiation may cause damage to the drug and the EO gas method is pharmaceutically unacceptable as a method to sterilize the implant formulation.
- the formulation may be prepared under sterilized conditions, such methods are very expensive to the extent that the practicability of the preparation may be lowered.
- a composition for use as an implant which can be prepared by a simple procedure, and which releases the drug over a long period and which is administered by a single injection and which can decompose into materials harmless to human body is needed.
- the present invention provides a liquid composition of a drug delivery implant, which slowly releases the active substance over a prolonged period, which is administered by a single injection and which can then decompose into materials harmless to the human body and be excreted.
- the liquid polymeric composition of the present invention comprises a water- soluble biocompatible liquid polyethylene glycol derivative, a biodegradable block copolymer, which is insoluble in water but soluble in the water-soluble biocompatible liquid polyethylene glycol derivative, and a pharmacologically or physiologically active substance.
- the present invention is directed to a liquid polymeric composition containing a water-soluble biocompatible liquid polyethylene glycol derivative, a biodegradable block copolymer which is water-insoluble but which can be dissolved in the water-soluble biocompatible liquid polyethylene glycol derivative, and a pharmacologically and physiologically active substance.
- the liquid composition of the present invention forms a polymeric implant, containing a physiologically active substance, which, when it is injected into a living body, then slowly releases the active substance over a prolonged period of time and is then decomposed into materials harmless to the human body and excreted.
- the biodegradable block copolymer is a polymer which is not dissolvable in an aqueous solution but is dissolvable in a low molecular weight polyethylene glycol or derivative thereof.
- the biodegradable block copolymer can be hydrolyzed with water to materials harmless to human body, and serves as a drug reservoir when administered.
- This copolymer is preferably a block copolymer formed by ester bonding of a hydrophobic polyester (A) block and a polyethylene glycol (B) block.
- the biodegradable block copolymer is a di- or tri-block copolymer comprising biodegradable hydrophobic polymer A block component and a hydrophilic polymer B block component.
- the type of block linkage of the copolymer can be A-B-A, B-A-B, A-B or (A-B) n where n is an integer of from about 2 to 20
- the A-B-A type block is preferred.
- the molecular weight of the biodegradable block copolymer is preferably within the range of 1,000 to 50,000 Daltons, more preferably within the range of 1 ,000 to 15,000 Daltons and most preferably within the range of 1 ,000 to 10,000 Daltons
- the hydrophobic polyester (A) block can be a member selected from the group consisting of L-polylactide (L-PLA), D,L-polylactide (D,L-PLA), a copolymer of L- or D,L- lactide with glycolide (PLLGA or PDLLGA), polyglycolide (PGA), polycaprolactone (PCL), a copolymer of lactic acid with caprolactone (PLCL), polyhydroxy butyric acid (PH
- the hydrophobic polyester (A) block is a member selected from the group consisting of L-polylactic acid (L-PLA), D,L-polylactic acid (D,L-PLA), a copolymer of L- or D,L-lactic acid with glycolic acid, and a copolymer of 1 ,4-dioxan-2-one with lactide.
- the molecular weight of the hydrophobic polyester (A) block is preferably within the range of 500 to 25,000 Daltons, more preferably within the range of 500 to 15,000 Daltons and most preferably within the range of 1,000 to 5,000 Daltons.
- the hydrophilic polymer B block of the biodegradable copolymer is preferably a member selected from the group consisting of polyethylene glycol (PEG), a copolymer of ethylene glycol and propylene glycol and derivatives thereof. More preferably, the hydrophilic polymer B block is a polyethylene glycol derivative.
- the molecular weight of the hydrophilic polymer B block is preferably within the range of 100 to 10,000 Daltons, and more preferably within the range of 500 to 5,000 Daltons.
- the content of the hydrophilic polymer B block is preferably within the range of 20 to 80 wt%, and more preferably within the range of 40 to 70 wt%
- the content of the biodegradable block copolymer is preferably within the range of 5 to 80 wt%, and more preferably within the range of 20 to 60 wt% and most preferably within the range of 20 to 50 wt%
- the liquid polyethylene glycol derivative used in the present invention serves as a main constituent which dissolves or uniformly mixes with the biodegradable block copolymer and so reduces the viscosity of the total polymeric composition and increases the fluidity of the composition.
- the polymeric composition can be readily injected by means of a syringe of 18 to 23 gauge.
- the liquid polyethylene glycol derivative can dissolve when in contact with water or body fluids allowing the biodegradable block copolymer, containing the physiologically active substance, to solidify as an implant. Therefore, the liquid polyethylene glycol derivative of the present invention should be a material which cause neither decomposition or changes the properties of the biodegradable block copolymer, and further, does not cause loss of activity of the physiologically active substance.
- the liquid polyethylene glycol derivative is in the form of a polymer which is a liquid at room temperature.
- Polyethylene glycol derivatives suitable for the present invention include polyethylene glycol, dialkyl polyethylene glycol, diacyl polyethylene glycol, etc., which has the following formula (I): R'-XCH.CH ⁇ OCT ⁇ CH ⁇ -X-R 1 (I) in which R 1 is H, (CH 2 ) m CH 3 or CO(CH 2 ) m CH 3 , wherein m is an integer of 0 to 17;
- X is O, NH or S
- 1 is an integer of 1 to 100.
- the hydroxy groups of both ends of the liquid polyethylene glycol are protected to prevent them from decomposing the ester bonds of the polylactic acid or polyglycolic acid of the hydrophobic A block of the biodegradable block copolymer.
- the hydroxy groups of polyethylene glycol can be protected by etherification with an alkyl group or esterification with an acyl group
- the hydroxy groups are protected by esterification so that they can be hydrolyzed with water to materials harmless to the human body Esterification also increases the affinity of the liquid polyethylene glycol derivative for the biodegradable block copolymer and minimizes the phase separation in the liquid polymeric composition Therefore, it is particularly preferred to use a polyethylene glycol derivative wherein ester groups are introduced in order to increase compatibility with the biodegradable block copolymer
- the liquid polyethylene glycol derivative has an affinity for the biodegradable block copolymer and does not cause phase separation or induce the decomposition of the ester groups of the hydrophobic A block polymer
- liquid polyethylene glycol derivatives include those having hydroxy groups at both ends which are protected with ester groups, and which are further esterified with dicarboxyhc acid to increase the content of ester groups, as in the following formula (II)
- R 2 OOC(CH 2 ) q C(O)(OCH 2 CH 2 ) p -OC(O)(CH 2 ) q COOR 2 (II) in which R 2 is (CH 2 ) X CH 3 , wherein x is an integer of 0 to 17, H, Na, Ca, Mg or Zn, p is an integer of 1 to 100, and q is an integer of 0 to 6
- polymers of formula (II) above can be obtained by reacting polyethylene glycol with an anhydride of dicarboxyhc acid such as malonic acid, succinic acid, gluta ⁇ c acid, etc to obtain dicarboxy polyethylene glycol which is treated with thionyl chloride to change the carboxy groups into acyl chlorides and then treated with an alcohol to obtain an ester
- the molecular weight of the polyethylene glycol derivative is within the range of 100 to 15,000 Daltons, more preferably within the range of 200 to 1 ,000 Daltons
- the content of the liquid polyethylene glycol derivative is preferably within the range of 10 to 95 wt%, and more preferably within the range of 30 to 70 wt%.
- the "physiologically active substance” or “the drug” refers to a substance which has a water solubility of 1 ⁇ g/ml or more and inhibits the growth of microorganisms, viruses, etc., or stimulates or inhibits the physiological function of a warm blooded animal or human body.
- physiologically active substances include antibacterial agents, anti-inflammatory agents, anticancer agents, growth hormones, antimalarial agents, hormones, immunostimulants, growth factors, antipyretics, antidepressants, immunodepressants, antiemetics, agents for treatment of diabetes, antihypertensive agents, antihyperlipidemic agents, agents for treatment of cardiovascular disorders, and the like.
- antibacterial agents which can be used in the present invention include minocycline, tetracycline, ofloxacin, phosphomycin, mergain, profloxacin, ampicillin, penicillin, doxycycline, thienamycin, cephalosporin, norcadicin, gentamycin, neomycin, kanamycin, paromomycin, micronomycin, amikacin, tobramycin, dibekacin, cefotaxim, cephaclor, erythromycin, ciprofloxacin, levofloxacin, enoxacin, vancomycin, imipenem, fucidic acid and mixtures thereof.
- anti-inflammatory agents which can be used in the present invention include lysozyme, acetaminophen, aspirin, ibuprofen, diclofenac, indomethacin, piroxicam, fenoprofen, flubiprofen, ketoprofen, naproxen, suprofen, loxoprofen, cinoxicam, tenoxicam and mixtures thereof
- the present invention is particularly useful for delivering drugs, for example, peptide and protein drugs, which require daily administration for a long period of time, have a high molecular weight and are difficult to absorb through the gastrointestinal tract or skin
- drugs include human growth hormone (hGH), porcine growth hormone (pGH), leukocyte growth factor (G-CSF), erythrocyte growth factor (EPO), macrophage growth factor (M-CSF), tumor necrosis factor (TNF), epithelial growth factor (EGF), platelet- derived growth factor (PDGF), interferon- ⁇ , ⁇ , ⁇ (IFN- ⁇ , ⁇ , ⁇ ), interleukin-2 (IL-2), calcitonin, nerve growth factor (NGF), growth hormone releasing factors, angiotensin, luteinizing hormone releasing hormone (LHRH), LHRH agonist, insulin, thyrotropin releasing hormone (TRH), angiostatin, endostatin, somatostatin, glucagon, endorphin, baci
- the content of said physiologically active substance in the liquid polymeric composition of the present invention is preferably within the range of 1 to 40 wt%, and more preferably within the range of 1 to 30 wt% and most preferably within the range of 2 to 25 wt%
- the liquid polymeric composition of the present invention can further contain a pharmaceutically acceptable additive in order to improve the stability of the drug in the polymeric composition, and to control the concentration of hydrogen ion in the composition or to control the release rate of the drug and the decomposition rate of polymer
- a pharmaceutically acceptable additive is preferably selected from the group consisting of surfactants, inorganic salts, sugars, natural polymers and mixtures thereof
- ionic or non-ionic surfactants may be used in the composition of the present invention, however, non-ionic surfactants are preferred
- Typical ionic surfactants include sodium dodecylsulfate and typical non-ionic surfactants include polysorbate, polyvinylpyrrolidone, poloxamers, glyceryl monooleate, glyceryl monostearate, polyoxyethylene alkyl ether and mixtures thereof
- the sugars which can be used as additives in the present invention include mannitol, sorbitol, glucose, xylit
- the liquid polymeric composition according to the present invention can be prepared by a process which comprises the steps of mixing and dissolving a water-soluble biocompatible liquid polyethylene glycol derivative, a biodegradable block copolymer which is insoluble in water but soluble in said water-soluble biocompatible liquid polyethylene glycol derivative, and a physiologically active substance, in an organic solvent or mixture of an organic solvent and water to obtain a polymeric solution wherein the ratio of the organic solvent and water is within the range of 0.2/0 8 to 0 8/0 2, sterilizing the polymeric solution by filtration through a membrane and removing the organic solvent by lyophilizing or evaporating the filtered polymeric solution under reduced pressure.
- the liquid polymeric composition of the present invention can be prepared by a process which comprises the steps of preparing a solution of one or more member selected from the group consisting of a water-soluble biocompatible liquid polyethylene glycol derivative, a biodegradable block copolymer which is insoluble in water but soluble in said water-soluble biocompatible liquid polyethylene glycol derivative, and a physiologically active substance, in an organic solvent or mixture of an organic solvent and water to obtain a solution wherein the ratio of the organic solvent and water is within the range of 0.2/0 8 to 0 8/0 2, sterilizing the respective solution by filtration through a membrane, mixing the filtered solution and removing the organic solvent by lyophilizing or evaporating the mixed solution under reduced pressure
- the liquid polymeric composition of the present invention can be prepared according to the following manner Firstly, the biodegradable block copolymer, the liquid polyethylene glycol derivative, the physiologically active substance and optionally the additives are dissolved together in an organic solvent or mixture of an organic solvent and water to prepare the polymer solution
- suitable organic solvents for preparing the polymer solution include acetonitrile, acetone, acetic acid, dimethyl acetamide, ethanol, isopropanol, dioxane, etc
- the organic solvent is used in combination with water with a mixing ratio of solvent to water within the range of about 0 2/0 8 to 0 8/0 2
- the resulting polymer solution is sterilized by filtering through a membrane filter having a pore size of 0 8 to 0 22 ⁇ m
- the organic solvent and water are then removed by lyophilization or evaporation, under reduced pressure, in preparation of the liquid polymeric composition
- the polymer solution containing the physiologically active substance is prepared by making the polymer solution out of an organic solvent and water
- the resulting solution may be frozen and then lyophilized
- the lyophilization is carried out by removing excess solvent from the solution at a temperature below 30 °C, under a reduced pressure of below about 0 1 torr
- the liquid polymeric composition is then dried by vacuum under reduced pressure until the water content is below 1%, and preferably below 0 5% During vacuum drying, it is preferred that the liquid composition is stirred with a mixer so that the physiologically active substance can be uniformly distributed If the organic solvent is used without water, the liquid composition is preferably slowly evaporated under reduced pressure without lyophilization
- composition of the present invention may also be prepared by dissolving in the organic solvent, one or more components selected from the group consisting of the biodegradable block copolymer, the liquid polyethylene glycol derivative, the physiologically active substance and additives, to prepare the respective solution, which is then individually filtered through a membrane filter and then mixed to obtain the liquid composition of the present invention
- liquid polymeric composition containing the physiologically active substance can be dispensed into a disposable syringe in the amount required for a single dose The syringe is then sealed in order to prepare the ready-to-use drug-containing liquid polymeric composition for implanting
- the liquid polymeric composition of the present invention eliminates the possibility of histotoxicity such as tissue dehydration, necrosis and pain that is caused by organic solvent when the composition is injected into tissues.
- the hydrolysis of the biodegradable polymer can be prevented.
- the biodegradable block copolymer is dissolved in low molecular polyethylene glycol, the composition can be sterilized by membrane filtration.
- the composition of the present invention forms an implant when injected. From the implant the drug can be slowly released. The implant is then decomposed into materials harmless to the human body and is then excreted after the drug release is completed.
- Figure 1 shows the result of in vitro drug release tests for the liquid polymeric compositions of the present invention.
- Figure 2 shows the result of stability tests for the liquid polymeric composition of the present invention.
- Block copolymers (PLA-PEG-PLA) of polylactide (PL A) and polyethylene glycol (PEG), or block copolymers (PLGA-PEG-PLGA) of copolymer (PLGA) of lactide and glycolide and polyethylene glycol (PEG).
- a . hydrophobic polymer (polylactide or copolymer of lactide and glycolide)
- hydrophilic polymer polyethylene glycol
- a Block copolymer made of a copolymer (PLDO) of lactide and l,4-dioxan-2-one, and polyethylene glycol (PEG)
- LA lactide
- DO l,4-dioxan-2-one
- hydrophobic polymer (copolymer of lactide and l,4-dioxan-2-one)
- hydrophilic polymer polyethylene glycol
- Disuccinyl polyethylene glycol 25 g, about 50 mmol as prepared in the above (2) was dissolved in benzene, and then thionyl chloride (14 g, 117 mmol) was added. The mixture was refluxed for 12 hours and then distilled under vacuum to remove benzene. The resulting reaction product was cooled to 0 °C and then excess ethanol (10 ml) was added. When reaction heat was no longer being generated, a condenser was added to the reaction vessel and the reaction mixture was refluxed for 30 minutes.
- Example 1 100 mg of human growth hormone, 400 mg of the biodegradable block copolymer (PLA-PEG-1) synthesized above, 450 mg of liquid polyethylene glycol (MW 300) and 50 mg of gelatin were dissolved in 60% aqueous acetic acid solution obtaining a polymer solution.
- the polymer solution was then sterilized by filtering through a membrane filter having a pore size of 0.22 ⁇ m.
- the organic solvent and water were then removed from the polymer solution by lyophilization leaving a drug-containing liquid polymeric composition.
- the drug-containing liquid polymeric composition obtained was then filled in a sterilized disposable syringe in the amount of a single dose, which was then sealed.
- pac taxel 60 mg of pac taxel, 300 mg of the biodegradable block copolymer (PLA-PEG- 1 ) synthesized above, 600 mg of polyethylene glycol (MW 300), 20 mg of poloxamer-188 and 20 mg of xylitol were dissolved in a 70% aqueous ethanol solution and the drug-containing liquid polymeric composition was then prepared according to the same procedure as Example 1.
- piroxicam 150 mg of piroxicam, 400 mg of the biodegradable block copolymer (PLDO-PEG-2) synthesized above, 420 mg of diacetyl polyethylene glycol (DA-PEG, MW 600) and 30 mg of gelatin were dissolved in a 50% aqueous acetic acid solution and the drug-containing liquid polymeric composition was then prepared according to the same procedure as Example 1.
- PLDO-PEG-2 biodegradable block copolymer synthesized above
- DA-PEG diacetyl polyethylene glycol
- gelatin 30 mg
- Test 1 In vitro drug release test
- the liquid drug containing polymeric composition of the present invention is capable of forming a polymeric mass when contacted with an aqueous environment and is useful for sustained drug delivery.
- Test 2 Test for stability of the liquid polymeric composition
- Example 10 PLA-PEG-PLA (1090-1000-1090) i g Dimethyl polyethylene glycol (MW 350) 5 g
- Each of the liquid polymeric compositions as prepared above were added to a cylindrical glass container having a diameter of 1 cm and a height of 5 cm to a height of 4 cm and then allowed to stand at 25 °C and then 4 °C. At given times, 0.2 ml of each of both the supernatant and bottom solution were collected and then dissolved in 2 ml of distilled water and the content of the deposited hydrophobic polymer was analyzed.
- the stability of the composition was determined from the rate of contents of polymer in the bottom solution and the supernatant Specifically, when the rate of the content of polymer in the bottom solution/the content of polymer in the supernatant was 1 0, the composition was determined to be stable, whereas at a rate below 1 0, it was determined that the phase separation had occurred The result thereof is shown in Figure 2 From Figure 2, it can be seen that the compositions of the present invention maintain a uniform composition over 100 days whereas in all of the comparative compositions phase separation occurs between 10 and 30 days.
- the biodegradable block copolymer is dissolved in a low molecular polyethylene glycol
- the composition can be sterilized by membrane filtration and directly implanted through a simple injection.
- the drug can be slowly released from the implant which can then decompose into materials harmless to the human body and be excreted after the drug is completely released. Therefore, the liquid polymeric composition of the present invention is very useful as sustained delivery system for physiologically active substances such as peptides and proteins.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002395077A CA2395077C (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
MXPA02006272A MXPA02006272A (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof. |
EP00989005.4A EP1244471B1 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
US10/169,012 US6916788B2 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
JP2001546681A JP3614820B2 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and method for producing the same |
AU25550/01A AU779713B2 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
ES00989005T ES2433010T3 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block colorimeter for drug delivery system and process for the preparation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-0060349A KR100416242B1 (en) | 1999-12-22 | 1999-12-22 | Liquid composition of biodegradable block copolymer for drug delivery and process for the preparation thereof |
KR1999/60349 | 1999-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001045742A1 true WO2001045742A1 (en) | 2001-06-28 |
Family
ID=19628082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2000/001508 WO2001045742A1 (en) | 1999-12-22 | 2000-12-21 | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US6916788B2 (en) |
EP (1) | EP1244471B1 (en) |
JP (1) | JP3614820B2 (en) |
KR (1) | KR100416242B1 (en) |
CN (1) | CN1204924C (en) |
AU (1) | AU779713B2 (en) |
CA (1) | CA2395077C (en) |
ES (1) | ES2433010T3 (en) |
MX (1) | MXPA02006272A (en) |
WO (1) | WO2001045742A1 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003042300A1 (en) * | 2001-11-15 | 2003-05-22 | Biomatera Inc. | Method for preparing gels |
EP1375592A1 (en) * | 2002-06-17 | 2004-01-02 | National Institute of Advanced Industrial Science and Technology | Biodegradable polylactide resin composition |
WO2004103342A2 (en) * | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
WO2004105825A1 (en) * | 2003-01-10 | 2004-12-09 | Taki Chemical Co., Ltd. | Biomaterial for osteogenesis, injection preparation containing the material, kit for preparing the material and osteogenesis method using the same |
JP2005508946A (en) * | 2001-10-09 | 2005-04-07 | アストラゼネカ アクチボラグ | Pharmaceutical formulation |
EP1531797A1 (en) * | 2002-06-28 | 2005-05-25 | Macromed, Incorporated | Biodegradable block copolymeric compositions for drug delivery |
JP2005525375A (en) * | 2002-03-05 | 2005-08-25 | トランセイブ, インク. | Method for encapsulating biologically active substance in liposome or lipid complex |
WO2005120453A1 (en) * | 2004-06-09 | 2005-12-22 | Novartis Ag | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
EP1663296A1 (en) * | 2003-09-25 | 2006-06-07 | Cangene Corporation | Liquid human growth hormone formulation containing polyethylene glycol |
WO2006063350A2 (en) * | 2004-12-10 | 2006-06-15 | Talima Therapeutics, Inc. | Compositions and methods for treating conditions of the nail unit |
US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
EP1886666A1 (en) * | 2006-08-07 | 2008-02-13 | BIOTRONIK VI Patent AG | Method for manufacturing a composite made of oligo- or polynucleotide and hydrophobic biodegradable polymers and composite created according to this method |
EP2044959A1 (en) | 2003-06-26 | 2009-04-08 | pSivida Inc | In-situ gelling drug delivery system |
WO2009091103A1 (en) * | 2008-01-14 | 2009-07-23 | Korea Advanced Institute Of Science And Technology | Complex of biopolymers and insoluble biomolecules, and manufacturing method thereof |
WO2010018159A1 (en) * | 2008-08-12 | 2010-02-18 | Novartis Ag | Pharmaceutical compositions |
US7875677B2 (en) | 2001-04-20 | 2011-01-25 | The University Of British Columbia | Micellar drug delivery systems for hydrophobic drugs |
US20120052040A1 (en) * | 2003-11-20 | 2012-03-01 | Angiotech International Ag | Polymer compositions and methods for their use |
CN102585006A (en) * | 2012-02-27 | 2012-07-18 | 华中农业大学 | Monoclonal antibody, enzyme-linked immunosorbent assay (ELISA) method and kit for detecting neomycin, amikacin and paromomycin |
US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
US8591870B2 (en) | 2004-12-10 | 2013-11-26 | Hallux, Inc. | Compositions and methods for treating conditions of the nail unit |
WO2015004669A1 (en) * | 2013-07-11 | 2015-01-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Implantable markers |
US9023897B2 (en) | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
US9375558B2 (en) | 2013-03-14 | 2016-06-28 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
EP2997982A4 (en) * | 2013-05-13 | 2017-01-11 | A School Corporation Kansai University | Substance for preventing adhesion and production method therefor |
CN106692031A (en) * | 2015-08-21 | 2017-05-24 | 安徽中人科技有限责任公司 | Implant capable of releasing doxorubicin continuously for long term, and preparation method thereof |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US9999675B2 (en) | 2012-11-05 | 2018-06-19 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
US10058634B2 (en) | 2009-04-28 | 2018-08-28 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
WO2018227293A1 (en) * | 2017-06-13 | 2018-12-20 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
WO2019016236A1 (en) * | 2017-07-17 | 2019-01-24 | Medincell | Pharmaceutical composition |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
EP2509634B1 (en) * | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
CN113599355A (en) * | 2021-09-02 | 2021-11-05 | 河南省肿瘤医院 | Flurbiprofen injection and preparation method thereof |
US11865205B2 (en) | 2015-11-16 | 2024-01-09 | Medincell S.A. | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
KR100358027B1 (en) * | 2000-02-14 | 2002-10-25 | 한국과학기술연구원 | Biodegradable Triblock Copolymers and Process for Their Preparation |
US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US20040185101A1 (en) * | 2001-03-27 | 2004-09-23 | Macromed, Incorporated. | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
CA2463172C (en) * | 2001-10-18 | 2009-08-18 | Samyang Corporation | Polymeric micelle composition with improved stability |
CA2473931C (en) * | 2002-01-23 | 2010-10-26 | Dentsply International, Inc. | Irrigation solution and methods for use |
US8871241B2 (en) * | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
CA2530113C (en) * | 2003-06-26 | 2013-08-13 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
US7955616B2 (en) * | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
US7179867B2 (en) * | 2003-11-26 | 2007-02-20 | Industrial Technology Research Institute | Thermosensitive biodegradable copolymer |
CA2551510C (en) * | 2003-12-23 | 2013-07-30 | Pharmacia Corporation | Stable growth hormone liquid formulation |
JP2007517550A (en) * | 2004-01-02 | 2007-07-05 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Medical device coated with high density lipoprotein |
US8980300B2 (en) | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
KR20090010953A (en) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
KR100908517B1 (en) * | 2006-07-04 | 2009-07-20 | (주)아모레퍼시픽 | Sustained Release Porous Microparticles for Respiratory System Drug Delivery and Its Manufacturing Method |
EP2086513B1 (en) * | 2006-09-26 | 2016-09-07 | Samyang Biopharmaceuticals Corporation | Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
WO2008097901A1 (en) * | 2007-02-02 | 2008-08-14 | Tornier, Inc. | System and method for repairing tendons and ligaments |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US8642062B2 (en) * | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
KR100970922B1 (en) * | 2007-12-12 | 2010-07-16 | 한국콜마 주식회사 | Patch compositions being capable of phase transition at body temperature and improving skin elasticity, moisturization and drug penetration |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
US8497303B2 (en) * | 2008-01-18 | 2013-07-30 | Dow Global Technologies Llc | Method to enhance aqueous solubility of poorly soluble actives |
EP2103313A1 (en) * | 2008-03-19 | 2009-09-23 | Koninklijke Philips Electronics N.V. | Method for the synthesis of hollow spheres |
US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
EA020753B1 (en) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Therapeutic polymeric nanoparticles comprising vinca alkaloids, and use thereof |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
PT2774608T (en) * | 2008-06-16 | 2020-01-17 | Pfizer | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2213307A1 (en) * | 2009-02-03 | 2010-08-04 | Novartis AG | Injectable depot formulations |
WO2010068866A2 (en) * | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (en) * | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | Long-circulating nanoparticles for sustained release of therapeutic agents |
CA2763365C (en) | 2009-05-29 | 2016-09-13 | Cydex Pharmaceuticals, Inc. | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
RU2565668C2 (en) * | 2009-09-18 | 2015-10-20 | Протерикс Медисинс Дивелопмент Лимитед | Polymers capable of recovery and reversible thermal gel-formation |
US9155722B2 (en) * | 2009-09-18 | 2015-10-13 | Protherics Salt Lake City, Inc. | Reconstitutable reverse thermal gelling polymers |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP2013515741A (en) * | 2009-12-23 | 2013-05-09 | サイヴィーダ ユーエス,インコーポレイテッド | Sustained release delivery device |
US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
CN101816777B (en) * | 2010-04-27 | 2013-07-10 | 中国医学科学院医药生物技术研究所 | Novel Boanmycin composition and preparation method thereof |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
KR101335624B1 (en) * | 2011-02-08 | 2013-12-02 | 이화여자대학교 산학협력단 | Sol-gel transition chitosan-polymer composite and uses of the same |
MX356097B (en) | 2012-09-17 | 2018-05-14 | Pfizer Inc Star | Process for preparing therapeutic nanoparticles. |
WO2014100417A1 (en) * | 2012-12-19 | 2014-06-26 | Blend Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of cancers |
SI3086793T1 (en) | 2013-12-24 | 2022-10-28 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction |
WO2015133580A1 (en) * | 2014-03-05 | 2015-09-11 | わかもと製薬株式会社 | Injectable poly(lactic acid)-containing composition |
PL3116547T3 (en) | 2014-03-14 | 2019-11-29 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
BR112016023858A2 (en) * | 2014-04-14 | 2017-08-15 | Akina Inc An Indiana Us Corp | hydrogel tissue dilators |
CA2946476C (en) | 2014-05-01 | 2022-08-30 | Ingell Technologies Holding B.V. | Liquid triblock copolymer |
WO2016076347A1 (en) | 2014-11-13 | 2016-05-19 | 東亞合成株式会社 | Method for introducing exogenous substance into cell, and material used in said method |
HRP20221024T1 (en) | 2014-12-09 | 2022-11-11 | Sweetwater Energy, Inc. | Rapid pretreatment |
CN107427610B (en) * | 2015-03-12 | 2021-09-17 | 库罗斯生物科学有限公司 | Anhydrous biocompatible composite material |
CN105017445B (en) * | 2015-06-30 | 2017-06-20 | 华南理工大学 | PH response star polymer and micella and composite based on beta cyclodextrin |
EP3583223A4 (en) | 2017-02-16 | 2020-12-23 | Sweetwater Energy, Inc. | High pressure zone formation for pretreatment |
WO2018169950A1 (en) * | 2017-03-13 | 2018-09-20 | The Johns Hopkins University | Injectable multidrug delivery hydrogel and uses thereof |
JP6403297B2 (en) * | 2017-05-02 | 2018-10-10 | 川澄化学工業株式会社 | Method for producing anti-adhesion material |
CN107550893B (en) * | 2017-09-05 | 2020-07-17 | 南宁师范大学 | Preparation method of acetaminophen-loaded nanofiber composite material |
MX2020014160A (en) * | 2018-06-25 | 2021-03-09 | Titan Pharmaceuticals Inc | Implants for release of lipophilic or amphiphilic pharmaceutical substances. |
CN109498804B (en) * | 2018-12-04 | 2022-07-26 | 中国人民解放军军事科学院军事医学研究院 | Temperature response type rabies vaccine delivery system |
GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
US20220152270A1 (en) * | 2019-03-05 | 2022-05-19 | Future University In Egypt | Long lasting biodegradable polymer based in-situ forming implant for treatment of bone injuries |
JP7201795B2 (en) * | 2019-03-29 | 2023-01-10 | 富士フイルム株式会社 | biomaterial |
BR112022012348A2 (en) | 2019-12-22 | 2022-09-13 | Sweetwater Energy Inc | METHODS OF MAKING SPECIALIZED LIGIN AND BIOMASS LIGIN PRODUCTS |
CN113117142B (en) * | 2020-01-14 | 2023-09-19 | 渼颜空间(河北)生物科技有限公司 | Biodegradable injection filler, preparation method and application thereof |
CN111888523A (en) * | 2020-09-08 | 2020-11-06 | 尹振宇 | Preparation method of polylactic acid gel for improving skin |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
WO1995027481A1 (en) * | 1994-04-08 | 1995-10-19 | Atrix Laboratories, Inc. | Liquid delivery compositions |
WO1996021427A1 (en) * | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
US5599552A (en) | 1989-07-24 | 1997-02-04 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5607686A (en) | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
CN1208616A (en) * | 1997-08-15 | 1999-02-24 | 安徽中人科技有限责任公司 | Sustained release and implantation type cis-platinum medicine and method for preparing same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844896A (en) * | 1987-11-02 | 1989-07-04 | Lim Technology Laboratories, Inc. | Microencapsulated insecticidal pathogens |
ZA964928B (en) * | 1995-06-13 | 1997-12-10 | American Home Prod | Oral formulations of S(+)-etodolac. |
US20020164374A1 (en) * | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
KR100289074B1 (en) * | 1998-02-04 | 2001-07-12 | 김윤 | Drug delivery systems as hydrophobic drug carriers |
KR100360827B1 (en) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
-
1999
- 1999-12-22 KR KR10-1999-0060349A patent/KR100416242B1/en active IP Right Grant
-
2000
- 2000-12-21 JP JP2001546681A patent/JP3614820B2/en not_active Expired - Fee Related
- 2000-12-21 US US10/169,012 patent/US6916788B2/en not_active Expired - Lifetime
- 2000-12-21 AU AU25550/01A patent/AU779713B2/en not_active Expired
- 2000-12-21 ES ES00989005T patent/ES2433010T3/en not_active Expired - Lifetime
- 2000-12-21 WO PCT/KR2000/001508 patent/WO2001045742A1/en active IP Right Grant
- 2000-12-21 EP EP00989005.4A patent/EP1244471B1/en not_active Expired - Lifetime
- 2000-12-21 MX MXPA02006272A patent/MXPA02006272A/en active IP Right Grant
- 2000-12-21 CN CNB008175802A patent/CN1204924C/en not_active Expired - Lifetime
- 2000-12-21 CA CA002395077A patent/CA2395077C/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599552A (en) | 1989-07-24 | 1997-02-04 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
WO1995027481A1 (en) * | 1994-04-08 | 1995-10-19 | Atrix Laboratories, Inc. | Liquid delivery compositions |
US5607686A (en) | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
WO1996021427A1 (en) * | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
CN1208616A (en) * | 1997-08-15 | 1999-02-24 | 安徽中人科技有限责任公司 | Sustained release and implantation type cis-platinum medicine and method for preparing same |
Non-Patent Citations (2)
Title |
---|
See also references of EP1244471A4 * |
TAKAOK ET AL.: "Problem and solution in the practical use of bone morphogenetic proteins", J. HARD TISSUE BIOL., vol. 5, no. 2, 1996, pages 133 - 141, XP008099519 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875677B2 (en) | 2001-04-20 | 2011-01-25 | The University Of British Columbia | Micellar drug delivery systems for hydrophobic drugs |
JP2005508946A (en) * | 2001-10-09 | 2005-04-07 | アストラゼネカ アクチボラグ | Pharmaceutical formulation |
US7754229B2 (en) | 2001-11-15 | 2010-07-13 | Laurent Masaro | Method for preparing gels |
CN100339441C (en) * | 2001-11-15 | 2007-09-26 | 生物材料公司 | Method for preparing gels |
WO2003042300A1 (en) * | 2001-11-15 | 2003-05-22 | Biomatera Inc. | Method for preparing gels |
JP2005525375A (en) * | 2002-03-05 | 2005-08-25 | トランセイブ, インク. | Method for encapsulating biologically active substance in liposome or lipid complex |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US9265836B2 (en) | 2002-06-11 | 2016-02-23 | Protherics Salt Lake City, Inc. | Biodegradable block copolymeric compositions for drug delivery |
EP1375592A1 (en) * | 2002-06-17 | 2004-01-02 | National Institute of Advanced Industrial Science and Technology | Biodegradable polylactide resin composition |
US6987138B2 (en) | 2002-06-17 | 2006-01-17 | National Institute Of Advanced Industrial Science & Technology | Biodegradable polylactide resin composition |
EP1531797A1 (en) * | 2002-06-28 | 2005-05-25 | Macromed, Incorporated | Biodegradable block copolymeric compositions for drug delivery |
EP2106787A3 (en) * | 2002-06-28 | 2010-10-13 | Protherics Salt Lake City, Inc. | Biodegradable block copolymeric compositions for drug delivery |
EP1531797A4 (en) * | 2002-06-28 | 2007-05-30 | Protherics Salt Lake City Inc | Biodegradable block copolymeric compositions for drug delivery |
US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
WO2004105825A1 (en) * | 2003-01-10 | 2004-12-09 | Taki Chemical Co., Ltd. | Biomaterial for osteogenesis, injection preparation containing the material, kit for preparing the material and osteogenesis method using the same |
WO2004103342A3 (en) * | 2003-05-16 | 2005-04-28 | Alkermes Inc | Injectable sustained release compositions |
WO2004103342A2 (en) * | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
EP2044959A1 (en) | 2003-06-26 | 2009-04-08 | pSivida Inc | In-situ gelling drug delivery system |
EP1663296A1 (en) * | 2003-09-25 | 2006-06-07 | Cangene Corporation | Liquid human growth hormone formulation containing polyethylene glycol |
EP1663296A4 (en) * | 2003-09-25 | 2009-11-25 | Cangene Corp | Liquid human growth hormone formulation containing polyethylene glycol |
US20120052040A1 (en) * | 2003-11-20 | 2012-03-01 | Angiotech International Ag | Polymer compositions and methods for their use |
WO2005120453A1 (en) * | 2004-06-09 | 2005-12-22 | Novartis Ag | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
AU2005251462B2 (en) * | 2004-06-09 | 2009-07-09 | Novartis Ag | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
US20140235555A1 (en) * | 2004-06-09 | 2014-08-21 | Novartis Ag | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
US9446009B2 (en) | 2004-12-10 | 2016-09-20 | Hallux, Inc. | Methods for treating conditions of the nail unit |
WO2006063350A3 (en) * | 2004-12-10 | 2006-10-19 | Talima Therapeutics Inc | Compositions and methods for treating conditions of the nail unit |
WO2006063350A2 (en) * | 2004-12-10 | 2006-06-15 | Talima Therapeutics, Inc. | Compositions and methods for treating conditions of the nail unit |
US8354095B2 (en) | 2004-12-10 | 2013-01-15 | Hallux, Inc. | Compositions and methods for treating conditions of the nail unit |
US8591870B2 (en) | 2004-12-10 | 2013-11-26 | Hallux, Inc. | Compositions and methods for treating conditions of the nail unit |
US8747820B2 (en) | 2004-12-10 | 2014-06-10 | Hallux, Inc. | Methods for treating conditions of the nail unit |
US8946292B2 (en) | 2006-03-28 | 2015-02-03 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
EP1886666A1 (en) * | 2006-08-07 | 2008-02-13 | BIOTRONIK VI Patent AG | Method for manufacturing a composite made of oligo- or polynucleotide and hydrophobic biodegradable polymers and composite created according to this method |
WO2009091103A1 (en) * | 2008-01-14 | 2009-07-23 | Korea Advanced Institute Of Science And Technology | Complex of biopolymers and insoluble biomolecules, and manufacturing method thereof |
AU2009281223B2 (en) * | 2008-08-12 | 2014-01-09 | Novartis Ag | Pharmaceutical compositions |
KR20110042309A (en) * | 2008-08-12 | 2011-04-26 | 노파르티스 아게 | Pharmaceutical compositions |
RU2504360C2 (en) * | 2008-08-12 | 2014-01-20 | Новартис Аг | Pharmaceutical compositions |
WO2010018159A1 (en) * | 2008-08-12 | 2010-02-18 | Novartis Ag | Pharmaceutical compositions |
KR101626632B1 (en) | 2008-08-12 | 2016-06-01 | 노파르티스 아게 | Pharmaceutical compositions |
US9155696B2 (en) | 2008-08-12 | 2015-10-13 | Novartis Ag | Pharmaceutical compositions |
US11027049B2 (en) | 2009-04-28 | 2021-06-08 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
US10058634B2 (en) | 2009-04-28 | 2018-08-28 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
EP2509634B1 (en) * | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
US9023897B2 (en) | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US10213528B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US10617793B2 (en) | 2011-05-20 | 2020-04-14 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US11529440B2 (en) | 2011-05-20 | 2022-12-20 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
CN102585006A (en) * | 2012-02-27 | 2012-07-18 | 华中农业大学 | Monoclonal antibody, enzyme-linked immunosorbent assay (ELISA) method and kit for detecting neomycin, amikacin and paromomycin |
US9999675B2 (en) | 2012-11-05 | 2018-06-19 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
US9375558B2 (en) | 2013-03-14 | 2016-06-28 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
US9498612B2 (en) | 2013-03-14 | 2016-11-22 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
US10456568B2 (en) | 2013-03-14 | 2019-10-29 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
EP2997982A4 (en) * | 2013-05-13 | 2017-01-11 | A School Corporation Kansai University | Substance for preventing adhesion and production method therefor |
WO2015004669A1 (en) * | 2013-07-11 | 2015-01-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Implantable markers |
CN106692031B (en) * | 2015-08-21 | 2019-08-06 | 安徽中人科技有限责任公司 | A kind of implant and preparation method thereof discharging adriamycin for a long time |
CN106692031A (en) * | 2015-08-21 | 2017-05-24 | 安徽中人科技有限责任公司 | Implant capable of releasing doxorubicin continuously for long term, and preparation method thereof |
US11865205B2 (en) | 2015-11-16 | 2024-01-09 | Medincell S.A. | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
WO2018227293A1 (en) * | 2017-06-13 | 2018-12-20 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
US11167034B2 (en) | 2017-06-13 | 2021-11-09 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
AU2018285975B2 (en) * | 2017-06-13 | 2023-11-16 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
US11666527B2 (en) | 2017-07-17 | 2023-06-06 | Medincell | Biodegradable block copolymer drug delivery composition |
WO2019016236A1 (en) * | 2017-07-17 | 2019-01-24 | Medincell | Pharmaceutical composition |
CN113599355B (en) * | 2021-09-02 | 2022-09-23 | 河南省肿瘤医院 | Flurbiprofen injection and preparation method thereof |
CN113599355A (en) * | 2021-09-02 | 2021-11-05 | 河南省肿瘤医院 | Flurbiprofen injection and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
AU779713B2 (en) | 2005-02-10 |
CN1413118A (en) | 2003-04-23 |
KR100416242B1 (en) | 2004-01-31 |
EP1244471B1 (en) | 2013-07-31 |
EP1244471A1 (en) | 2002-10-02 |
CN1204924C (en) | 2005-06-08 |
KR20010063314A (en) | 2001-07-09 |
CA2395077C (en) | 2008-07-08 |
EP1244471A4 (en) | 2009-10-21 |
JP2003517886A (en) | 2003-06-03 |
CA2395077A1 (en) | 2001-06-28 |
US6916788B2 (en) | 2005-07-12 |
US20030082234A1 (en) | 2003-05-01 |
JP3614820B2 (en) | 2005-01-26 |
ES2433010T3 (en) | 2013-12-05 |
AU2555001A (en) | 2001-07-03 |
MXPA02006272A (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2395077C (en) | Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof | |
US7833543B2 (en) | High viscosity liquid controlled delivery system and medical or surgical device | |
KR100933580B1 (en) | Biodegradable block copolymeric compositions for drug delivery | |
US7053209B1 (en) | High viscosity liquid controlled delivery system and medical or surgical device | |
KR101465994B1 (en) | Bioresorbable polymer matrices and methods of making and using the same | |
KR101741055B1 (en) | Biodegradable drug delivery compositions | |
US20080187568A1 (en) | Polymerization with precipitation of proteins for elution in physiological solution | |
AL et al. | Biodegradable polymers: Which, when and why? | |
RU2290950C2 (en) | Biodegradable composition with prolonged release of biologically active compound and method for its preparing | |
CZ49095A3 (en) | Pharmaceutical antimicrobial preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2001 546681 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 519555 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2395077 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/006272 Country of ref document: MX Ref document number: 008175802 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10169012 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 25550/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000989005 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000989005 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 519555 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 519555 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 25550/01 Country of ref document: AU |